Article
The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
Cancer medicine - 1 Feb 2024
Liu Fangfang, Zhang Xuemei, Lu Mengyao, Liu Chun, Zhang Xiaodong, Chu Qian, Chen Yuan, Zhang Peng
Abstract excerpt
BACKGROUND: The study focuses on PD-L1 expression as an essential biomarker for gauging the response of EGFR/ALK wild-type NSCLC patients to FDA-approved immune checkpoint inhibitors (ICIs). It aims to explore clinical, molecular, and immune microenvironment characteristics associated with PD-L1 expression in EGFR/ALK wild-type lung adenocarcinoma patients eligible for ICI therapy. METHODS: In this retrospective...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.